Farmakoterapi HT
-
Upload
muh-akbar-bahar -
Category
Documents
-
view
233 -
download
1
Transcript of Farmakoterapi HT
-
8/10/2019 Farmakoterapi HT
1/30
-
8/10/2019 Farmakoterapi HT
2/30
-
8/10/2019 Farmakoterapi HT
3/30
Introduction
Hypertension is a common disease that is simply defined as
persistently elevated arterial blood pressure (BP).
The risk of cardiovascular (CV) morbidity and mortality isdirectly correlated with blood pressure (BP). Even patients
with prehypertension have an increased risk of CV disease.
Etiology :- an unknown pathophysiologic etiology (essential or
primary hypertension).
- a specific cause of their hypertension (secondary
hypertension).
-
8/10/2019 Farmakoterapi HT
4/30
Genetic factors may play an important role in thedevelopment of essential hypertension.
Starting at a BP of 115/75 mm Hg, risk of CV disease
doubles with every 20/10 mm Hg increase.
Even patients with prehypertension have an increasedrisk of CV disease.
When a secondary cause is identified, removing theoffending agent (when feasible) or treating/correctingthe underlying comorbid condition should be the firststep in management.
Introduction
-
8/10/2019 Farmakoterapi HT
5/30
-
8/10/2019 Farmakoterapi HT
6/30
-
8/10/2019 Farmakoterapi HT
7/30
Classification of Blood Pressure in Adults
-
8/10/2019 Farmakoterapi HT
8/30
-
8/10/2019 Farmakoterapi HT
9/30
Potential Mechanisms of Pathogenesis
-
8/10/2019 Farmakoterapi HT
10/30
-
8/10/2019 Farmakoterapi HT
11/30
The RAA System
-
8/10/2019 Farmakoterapi HT
12/30
Clinical Presentation of Hypertension
-
8/10/2019 Farmakoterapi HT
13/30
Overall Goal of Therapy
The overall goal of treating hypertension is to reducehypertension associated morbidity and mortality.
This morbidity and mortality is related to target-organdamage (e.g., CV events, heart failure, and kidneydisease).
Reducing risk remains the primary purpose ofhypertension therapy and the specific choice of drugtherapy is significantly influenced by evidencedemonstrating such risk reduction.
-
8/10/2019 Farmakoterapi HT
14/30
Goal BP Values Recommended by AHA in 2007
-
8/10/2019 Farmakoterapi HT
15/30
Algorithm for treatment of hypertension.
-
8/10/2019 Farmakoterapi HT
16/30
Compelling indications for individual drug classes
-
8/10/2019 Farmakoterapi HT
17/30
-
8/10/2019 Farmakoterapi HT
18/30
-
8/10/2019 Farmakoterapi HT
19/30
-
8/10/2019 Farmakoterapi HT
20/30
-
8/10/2019 Farmakoterapi HT
21/30
Lifestyle Modification to Prevent and
Manage Hypertension
-
8/10/2019 Farmakoterapi HT
22/30
The rationale for dietary intervention in
hypertension
1. Hypertension is two to three times more likely inoverweight than in lean persons.
2. More than 60% of patients with hypertension areoverweight.
3. As little as 10 pounds of weight loss can decrease BPsignificantly in overweight patients.
4. Abdominal obesity is associated with the metabolicsyndrome, which is a precursor to diabetes,dyslipidemia, and, ultimately, CV disease.
5. Diets rich in fruits and vegetables and low insaturated fatlower BP in patients with hypertension.
6. Most people experience some degree of SBPreduction with sodium restriction.
-
8/10/2019 Farmakoterapi HT
23/30
Hypertension in Older People
Hypertension often presents as isolated systolic hypertension in the
elderly. Epidemiologic data indicate that CV morbidity and mortality are
more closely related to SBP than to DBP in patients ages 50 years
and older, so this population is at high risk for hypertension-related
target-organ damage Older patients with isolated systolic hypertension are often at risk
for orthostatic hypotension when antihypertensive drug therapy is
started, particularly with diuretics, ACE inhibitors, and ARBs.
Although overall treatment should be the same, low initial dosesshould be used and dosage titrations should be gradual to minimize
risk of orthostatic hypotension.
Centrally acting agents and -blockers should generally be avoided
or used with caution in the elderly because they are frequently
associated with dizziness and postural hypotension
-
8/10/2019 Farmakoterapi HT
24/30
Hypertension in Children and Adolescents
Equal to or greater than 120/80 mm Hg in adolescents, isconsidered prehypertension.
Hypertensive children often have a family history of highBP, and many are overweight, predisposing them to insulin
resistance and associated CV disease.
Unlike hypertension in adults, secondary hypertension ismore common in children and adolescents. An appropriateworkup for secondary causes is essential if elevated BP is
identified.
Kidney disease (e.g., pyelonephritis, glomerulonephritis) isthe most common cause of secondary hypertension inchildren.
-
8/10/2019 Farmakoterapi HT
25/30
Nonpharmacologic treatment, particularly weight lossin those who are overweight, is the cornerstone oftherapy for essential hypertension in children.
ACE inhibitors, ARBs, -blockers, CCBs, and thiazide-type diuretics are all acceptable choices in children.
ACE inhibitors, ARBs, and direct renin inhibitors arecontraindicated in sexually active girls because ofpotential teratogenic effect, and in those who mighthave bilateral renal artery stenosis or unilateralstenosis in a solitary kidney.
Hypertension in Children and Adolescents
-
8/10/2019 Farmakoterapi HT
26/30
Pregnancy
Hypertension during pregnancy is a major cause of maternaland neonatal morbidity and mortality.
Preeclampsia, defined as a elevated BP greater than or equalto 140/90 mm Hg that appears after 20 weeks gestationaccompanied by new-onset proteinuria (300 mg/24 hours),can lead to life-threatening complications for both motherand fetus.
Eclampsia, the onset of convulsions in preeclampsia, is amedical emergency.
Gestational hypertension is defined as new-onsethypertension arising after midpregnancy in the absence ofproteinuria, and chronic hypertension is elevated BP that isnoted before the pregnancy began.
-
8/10/2019 Farmakoterapi HT
27/30
-
8/10/2019 Farmakoterapi HT
28/30
Parameter laboratorium untuk masing-masing obat
dan asuhan kefarmasian
-
8/10/2019 Farmakoterapi HT
29/30
Efek samping dan kontraindikasi obat-obat
antihipertensi
-
8/10/2019 Farmakoterapi HT
30/30
Interaksi antara obat antihipertensive dengan obat lain